Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Post by Busyzzindahouseon Jan 04, 2018 10:09pm

135 Views

Post# 27286416

All the new KALY holders chk out the investor presentation

https://kalytera.co/wp-content/uploads/2017/12/Kalytera-Corporate-Presentation-December-2017.pdf

The GVHD market has grown at a compound annual growth rate (“CAGR”) of 6.59% since 2013, and is expected to be approximately $407M in 2018 (generic immuno-suppressants / no approved drug)

Bullboard Posts

Cross border trading in Canada and Australia